Objective In women with heart disease (HD), the third stage of labour is managed with a reduced dose of oxytocin because it can have significant adverse cardiovascular effects. However, women with HD have high rates of postpartum haemorrhage (PPH); consequently, we designed a prospective study to investigate whether higher doses of oxytocin can be given safely and would reduce rates of PPH. Methods We performed a single centre, prospective, cohort study comparing the standard 'low-dose' oxytocin infusion (10 U of oxytocin in 500 mL of normal saline given intravenously at 36 mL/hour for 4 hours (12 mU/ min), n=29) to the low-dose infusion and an additional 2 U of oxytocin given over 10 min immediately after birth (n=30). Maternal blood pressure was measured every minute for 10 min, continuous ECG (Holter) monitoring was performed and any symptoms (chest pain, dyspnoea) were recorded. Total blood loss and serum troponins were measured at 12 hours. Results There were no cardiac symptoms, arrhythmias, change in the ST segment or increase in serum troponins. The fall in blood pressure and increase in heart rate were greater with the additional oxytocin, but neither were statistically or clinically significant. The blood loss was significantly less in women receiving additional oxytocin (505 vs 849 mL) and the proportion of women having a PPH was lower. Conclusions The use of an additional 2 U of oxytocin for the management of third stage in women with HD had no cardiac consequences and was associated with a significantly lower blood loss. Further larger studies on a larger population of women with HD are needed.
INTRODUCTION
Current guidance on the management of labour in women with heart disease (HD) relies entirely on expert opinion. 1 It is surprising that there are no randomised or even prospective observational studies of labour in this population given that they have a greater morbidity during labour. Without contemporary, robust evidence, we are unable to improve the care we provide to this high-risk group of patients.
Postpostpartum haemorrhage (PPH) defined as blood loss ≥500 mL at vaginal delivery and ≥1000 mL at caesarean section; it is common and affects up to about 5% of women giving birth. 2 PPH rates are increasing not only due to better measurement of blood loss but also due to the combination of obstetric variables. 3 For many years, women with HD have been shown to beat greater risk of PPH, but only recently have studies begun to examine the reasons for this. 4 We have shown that uterine atony is the main factor responsible for PPH in women with HD, 5 as with the normal population, but that anticoagulant usage and mode of delivery were particularly important. It is possible that restrictive usage of uterotonic agents that is advocated by many expert groups for third-stage labour management contributes to higher rates of PPH and in turn results in greater blood loss at delivery. 1 6 The most commonly used uterotonic agent for third-stage management is oxytocin, which, when given rapidly as a high-dose bolus intravenously, causes marked hypotension and tachycardia. 7 Furthermore, ergometrine, which may be used in combination with oxytocin for the prevention of PPH, 8 can cause marked hypertension and coronary artery spasm. 9 For these reasons, ergometrine is usually avoided completely and lower than average doses of oxytocin are given. Evidence from the Cochrane database supports the routine use of oxytocin at any dose for prophylaxis against PPH, but reports that 10 IU is probably the most effective. 10 The European Society of Cardiology (ESC) suggests a slow bolus of 2 U of oxytocin for third-stage management for women with HD but presents no supportive evidence. 1 In our centre, we have used a 'low-dose' oxytocin infusion (10 U of oxytocin diluted in 500 mL of normal saline given at a rate of 36 mL/hour for 4 hours (12 mU/min)) in women with HD over the last 20 years and have observed high rates of PPH in such women at 23%. 4 The aim of this study was to examine the hypotheses that giving as low (over 10 min) bolus of 2 IU of oxytocin, in addition to the usual 'low-dose' oxytocin infusion for the management of third stage of labour does not increase adverse cardiovascular events (arrhythmia, chest pain, documented ST segment changes) and reduces blood loss at delivery.
METHODS
We conducted a single centre prospective cohort study that ran between September 2015 and June 2016. As routine patient care was agreed by the clinical team and altered to reflect this study and patients were not randomised, ethical approval was not needed.
Patient population
All women with underlying cardiac disease (congenital or acquired) who attended the obstetric cardiac clinic and delivered at Chelsea and Westminster Hospital were eligible to be included in the study. Women were not studied if we provided their antenatal care, but they delivered elsewhere, or if they developed features of maternal sepsis in labour (temperature >37.8°C on two occasions, or positive blood or urine cultures).
Intervention
The original study design was a prospective randomised controlled trial involving 60 subjects, but because of financial constraints we altered the design to a cohort study; 11 the first 30 women studied received the 'low-dose' infusion while for the next 30 women we changed our routine clinical policy and the women received an additional slow bolus injection of 2 IU of oxytocin. All women were given an explanation of the study and gave informed consent for additional monitoring. All women recruited were fitted with a Holter monitor (Spacelabs) at least 30 min before and for at least 12 hours after the administration of oxytocin. A cardiac physiologist blinded to the oxytocin regimen reviewed the Holter recordings. Blood levels of troponin (serum troponin T) were measured 12 hours after commencing the oxytocin infusion. As oxytocin can cause hypotension and tachycardia, both undesirable effects in women with cardiac disease, blood pressure (BP) and heart rate (HR) were monitored every minute for the first 10 min from oxytocin administration. Prior to undertaking this study, it was agreed by three obstetric anaesthetists and three adult congenital cardiologists (using the Delphi technique) that a maximal change in BP and HR of 10% would be acceptable following the additional dose of oxytocin; any change greater than this would be deemed undesirable. We documented the use of the vasopressor agent phenylephrine as this is commonly used in obstetric practice to counteract the hypotension resulting from regional anaesthesia, the use of oxytocin or blood loss.
Outcomes
The study tested two hypotheses, that the additional slow bolus injection of 2 U of oxytocin would (1) not increase the rate of both short-term (up to 10 min) effects on HR and BP and medium-term cardiovascular side effects (chest pain, ECG changes or heart failure) up to 12 hours following delivery. (2) Reduce the estimated blood loss following delivery, blood loss was estimated by weighing all swabs and pads and blood from suction bottles and subtracting the estimated weight of amniotic fluid.
Demographics, including parity and the underlying cardiac condition, for all subjects were recorded, including data on factors known to contribute to PPH, such as parity, maternal racial origin, maternal body mass index, duration of any oxytocin augmentation of the first stage of labour, duration of the second stage of labour, mode of delivery and birth weight. Women with any evidence of intra partum maternal sepsis were excluded from the study (sepsis is an important cause of PPH but is uncommon and was therefore an important potential confounder that would be difficult to control for). As cardiac disease is heterogeneous, a women's diagnosis was defined from the most clinically significant lesion. New York Heart Association (NYHA) scores were also calculated for all individuals.
Statistics
Analysis was performed using SPSS for Windows (v23). Data are presented as mean±SD or, if data were not normally distributed, median with range. Two-tailed p values were calculated and the level of significance was set at p <0.05.
RESULTS
Sixty-one women were recruited. Two were excluded because of fever in labour with evidence of maternal sepsis (one urine positive culture for Escherichia coli and one confirmed blood culture with group A streptococcus). Overall, 29 women received the standard 'low-dose' oxytocin regimen while the remaining 30 women received this regimen with the addition of a slow bolus of 2 U of oxytocin (high dose). The baseline demographic details and recorded blood loss at delivery of all women are shown in table 1. The demographic characteristics of both study groups were similar except that the women in the low-dose group were significantly younger at delivery, mean age 30.2 vs 33.1 years in the high-dose group ( p=0.03). Gestation at delivery and birth weight was similar in both groups. More women in the high-dose group were delivered by emergency caesarean section, but this was not statistically significant (p=0.20). The elective caesarean section rate was similar in both groups. Two patients required general anaesthesia in the high-dose group-one because of Harrington rods ( patient with Marfan syndrome and scoliosis) and one had an ineffective regional block at caesarean section and so needed conversion to general anaesthesia. Estimated blood loss at delivery was significant less in the high-dose group ( p=0.002) (mean blood loss 505 mL SD 326 mL vs 849 mL SD 440 mL) (figure 1). The cardiac conditions of the study population are shown in table 2 with corresponding modified World Health Organisation scores and whether the patient had been on low molecular weight heparin prior to delivery. The cohort was heterogeneous in relation to the severity of cardiac lesions encountered although no one had pulmonary hypertension. In women with mixed valvular disease, classification was based on the most clinically significant lesion. There were only two women (one in each group) with severe aortic stenosis (mean gradient >40 mm Hg), and two women (again one in each group) who had impaired systemic ventricular function (ejection fraction <50%). In total, 24/29 women in the standard treatment group had congenital HD as their primary lesion and 27/30 in the additional 2 IU group.
Analysis of Holter monitors showed that no individuals had any episodes of arrhythmia as a direct result of receiving oxytocin. Nor were there any episodes of ST segment change. One woman (transposition of great arteries with arterial switch) had a supraventricular tachycardia during elective caesarean section (indication previous caesarean section) prior to administration of oxytocin and this was terminated with intravenous metoprolol. Analysis of troponins (serum troponin T) also showed no cases with an elevated level at 12 hours after administration of oxytocin (all results <0.01 ng/mL).
When assessing for haemodynamic change associated with oxytocin, we found that there was an initial significant elevation in HR in both the low-dose group and the high-dose group (figure 2). The increase in HR from baseline (the value immediately before the injection of the oxytocin) to the first minute after administration was greater in the high-dose group, and was most significant at the first administration of oxytocin where the mean increase in HR from baseline was 7 bpm as compared with 4 bpm in the low-dose group (both highly significant p<0.001). While the increase was significant in both groups, there was no significant difference in the response to oxytocin between the groups. Measurement of systolic BP demonstrated a significant drop in both systolic and diastolic BP from baseline in both low-dose and high-dose groups (figures 3 and 4, both p<0.001). The fall was greatest in the high-dose group where it fell on average 8 mm Hg (systolic BP) from baseline and 6 mm Hg (diastolic) from baseline when recorded at 1 min, but the difference in the effect between groups was not significant. The drop appeared to plateau by about 4 min in both groups. Phenylephrine was used as a bolus dose(s) to counteract hypotension, which may have been due to either the effect of oxytocin or acute blood loss. It was only used in women who had a caesarean section or a trial of instrumental delivery in theatre. It was used in five cases of women who received the low-dose infusion (one forceps delivery in theatre and four cases of emergency caesarean section) and five cases of women who received the high-dose slow bolus (all were delivered by caesarean section). Repeated doses of phenylephrine were given largely in response to hypotension either as a result of the oxytocin or in cases of PPH. Blood loss at delivery was significantly greater in women who required phenylephrine compared with those who did not (mean blood loss 910 mL SD 490 mL vs 602 mL SD 390 mL, p=0.049).
Additional uterotonic agents (Misoprostol or Hemabate) were more commonly given in the low-dose group (7 vs 1 individuals, p=0.025). No women received ergometrine. Two women in the low-dose group received additional doses of oxytocin because of uterine atony (in both cases 1 U diluted in 5 mL of normal saline) given slowly over a minute. Only one patient in the whole cohort received a blood transfusion (2 units of packed red cells). This patient was in the low-dose group and her recorded blood loss at delivery (emergency caesarean section) was 1800 mL.
DISCUSSION
Our study has demonstrated that managing the third stage of labour in women with HD with an additional slow bolus of 2 IU does not cause any apparent clinically significant alteration in maternal cardiovascular parameters and significantly reduces blood loss at delivery. Our results also demonstrate that the proportion of women who had a blood loss of at least 1000 mL was much lower in those who received the additional 2 IU infusion (2/30 vs 13/30) revealing the clinical importance of the additional oxytocin. As uterine atony is the single largest cause of PPH, defining the dose of oxytocin that is both effective and safe in this group of patients is very important. 12 Published work from our group has previously shown that in cases of PPH in women with HD larger doses of oxytocin (usually 5 U as a slow bolus) have been given to patients without any ill effect. 5 However, the use of high-dose oxytocin (10 U) has been reported as being potentially causal in a case of a maternal death in a woman with pulmonary hypertension, 13 demonstrating the vulnerability of this patient group to the cardiovascular effects of oxytocin. HD is a spectrum and women with certain lesions will be more intolerant to cardiac changes caused by blood loss at delivery, the effect of autotransfusion from placental delivery and the negative chronotropic effect of oxytocin. Therefore, a universal oxytocin regimen may not be clinically appropriate.
Several authors have investigated the clinical outcomes when giving women without HD relatively lower doses of oxytocin for third-stage management. Sartain et al 14 compared a 2 IU infusion with a 5 IU infusion in women having caesarean section. They reported fewer cardiovascular changes (less profound drop in HR and BP) in those receiving the lower oxytocin dose, as well as demonstrating no requirement for additional uterotonic agents in this group. Bhattacharya et al 15 showed that oxytocin given as a rapid bolus rather than a slower infusion caused a greater cardiovascular response. Furthermore, oxytocin given at higher doses (10 U intravenously) for third-stage management is more likely to induce chest pain with concurrent Figure 4 Change in diastolic blood pressure with oxytocin.
ECG ST segment changes. 7 16 The effect of giving repeated doses of oxytocin (5 U) has also been studied in healthy individuals and showed that a second 5 IU dose of oxytocin produced a less pronounced haemodynamic change suggesting the development of tolerance or desensitisation of the endothelial oxytocin receptors. 17 This may be important in women with cardiovascular disease as giving repeated smaller doses of oxytocin maybe better tolerated. Equally, we found no difference in the HR and BP responses between the two regimens, suggesting that a slow infusion is well tolerated. HR and BP are suboptimal markers for changes in cardiac output and in future studies it would be better to directly evaluate cardiac output using a noninvasive method, which may allow subtle differences to be detected.
Langesaeter et al 18 performed a prospective study looking at regional anaesthesia and haemodynamic monitoring in women with HD. In their study, most women received bolus doses of IV oxytocin ranging from 0.05 to 0.5 U. They showed that only one patient out of 113 births experienced any significant symptoms as a result of oxytocin administration (dyspnoea) and that while systolic BP did fall as a result of oxytocin administration, in no cases was this clinically significant. However, they also reported that only about half of women undergoing caesarean section were able to do so without the need for phenylephrine, suggesting that some degree of hypotension is almost inevitable in women undergoing caesarean with regional blockade. A recent study evaluating the use of small prophylactic bolus doses of phenylephrine during low-dose spinal anaesthesia at caesarean section found that episodes of maternal hypotension were significantly reduced without an increase in the overall dose of phenylephrine being used. 19 It may be worth considering this regimen in women with more severe HD who may not tolerate hypotension well.
The use of additional uterotonic agents was also significantly lower in individuals who received the additional 2 IU oxytocin. It is likely that the higher recorded blood loss at delivery in the low-dose group prompted the operator to request the administration of additional uterotonic agents. However, as only one patient received a blood transfusion, we cannot comment as to whether the use of an additional 2 IU of oxytocin would reduce the need for blood transfusion.
Strengths and limitations
Our study is small and patients were not randomised; nevertheless, we are confident that there were no clinically relevant differences in the two groups. While there was heterogeneity in cardiac lesions in our cohort, we had relatively few women with the most severe cardiac lesions (one with a Fontan repair, and none with pulmonary hypertension and only two of our women were receiving anticoagulant therapy). Although our centre provides a regional service for congenital HD, we recognise that the reported sample is not necessarily representative of the total spectrum of women with HD who undergo pregnancy. As a result, only one patient was in NYHA class >1. Work from our group has shown women with a Fontan repair and pulmonary hypertension have a greater degree of haemorrhage at delivery; therefore, having more women with these lesions in our study may have influenced our results. 4 Given that the population of women with HD is heterogeneous and while the oxytocin regimen was well tolerated by all in the study, it is possible that other women would experience an adverse response to higher doses. Consequently, a larger randomised controlled trial of different oxytocin regimens is required. Furthermore, we recognise that there may be other variables that impact on maternal haemodynamics around delivery that we cannot control for such as maternal emotions and autotransfusion from the place when it is delivered.
CONCLUSION
Guidance from the ESC suggesting a 2 U infusion of oxytocin during the third stage of labour for women with HD is supported by our study. Our data suggest that this dose of oxytocin does not increase the risk of adverse cardiovascular events, provided that this additional dose is given slowly (over 10 min). Although we did not detect any adverse effects from this oxytocin regimen, it would seem prudent to adjust the dose of oxytocin according to the severity of the underlying HD until we have more data confirming safety in a larger population of women with HD.
Key messages
What is already known on this subject? Current evidence for the management of labour in women with heart disease (HD) is entirely based on expert opinion. This group of patients encounters greater obstetric morbidity in particular greater rates of postpartum haemorrhage which maybe poorly tolerated. Greater rates of haemorrhage are likely to be reflected by the management of third stage of labour and the restricted use of oxytocin.
What might this study add?
Our study has demonstrated that giving women oxytocin as a slow bolus (2 IU over 10 min) does not appear to adversely alter maternal parameters or induce arrhythmia or ST segment change. Women who were given this dose as compared with an established low dose (12 mU/hour) had a significantly reduced blood loss at delivery How might this impact on clinical practice? This study supports expert guidance from the European Society of Cardiology in managing women with HD in pregnancy. However, while we consider that this oxytocin regimen is safe for the management of the third stage of labour in the majority of women with HD, we need further studies to understand whether this is true of all women, particularly those with more severe forms of HD.
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